公司资料
Immunovant 股价、新闻与催化剂
- 股票代码:
- IMVT
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
37.65 USD (+3.49%)
收盘价
最后更新: 2026年9月17日
6.35B USD
市值
股价为何变动
截至 2026年9月17日，IMVT 上涨 3.49%，收于 $37.65。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Immunovant is an immunology company focused on FcRn inhibition for autoantibody-driven diseases.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Immunovant sits in clinical-stage autoimmune biotechnology.
商业模式特征
Its model is built around proof-of-concept data, dose optimization, and the potential to expand into multiple antibody-mediated diseases.
生物医药行业定位
Immunovant is a catalyst-heavy immunology name whose stock reacts to clinical differentiation and platform confidence.
未来催化剂
- Immunovant is heading into a more important stretch around IMVT-1402. Management's latest framing highlights Recent Highlights and Upcoming Milestones: The Company announced preliminary Week 16 (end of Period 1) results from the IMVT-1402 trial in D2T RA with ACR20, ACR50, and ACR70.... The stock is likely to react most to whether those milestones keep moving without a reset.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。